19 research outputs found
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP
The
protein methyltransferase (PMT) SETDB1 is a strong candidate
oncogene in melanoma and lung carcinomas. SETDB1 methylates lysine
9 of histone 3 (H3K9), utilizing <i>S</i>-adenosylmethionine
(SAM) as the methyl donor and its catalytic activity, has been reported
to be regulated by a partner protein ATF7IP. Here, we examine the
contribution of ATF7IP to the <i>in vitro</i> activity and
substrate specificity of SETDB1. SETDB1 and ATF7IP were co-expressed
and 1:1 stoichiometric complexes were purified for comparison against
SETDB1 enzyme alone. We employed both radiometric flashplate-based
and SAMDI mass spectrometry assays to follow methylation on histone
H3 15-mer peptides, where lysine 9 was either unmodified, monomethylated,
or dimethylated. Results show that SETDB1 and the SETDB1:ATF7IP complex
efficiently catalyze both monomethylation and dimethylation of H3K9
peptide substrates. The activity of the binary complex was 4-fold
lower than SETDB1 alone. This difference was due to a decrease in
the value of <i>k</i><sub>cat</sub> as the substrate <i>K</i><sub>M</sub> values were comparable between SETDB1 and
the SETDB1:ATF7IP complex. H3K9 methylation by SETDB1 occurred in
a distributive manner, and this too was unaffected by the presence
of ATF7IP. This finding is important as H3K9 can be methylated by
HMTs other than SETDB1 and a distributive mechanism would allow for
interplay between multiple HMTs on H3K9. Our results indicate that
ATF7IP does not directly modulate SETDB1 catalytic activity, suggesting
alternate roles, such as affecting cellular localization or mediating
interaction with additional binding partners
Identification of a peptide inhibitor for the histone methyltransferase WHSC1
<div><p>WHSC1 is a histone methyltransferase that is responsible for mono- and dimethylation of lysine 36 on histone H3 and has been implicated as a driver in a variety of hematological and solid tumors. Currently, there is a complete lack of validated chemical matter for this important drug discovery target. Herein we report on the first fully validated WHSC1 inhibitor, PTD2, a norleucine-containing peptide derived from the histone H4 sequence. This peptide exhibits micromolar affinity towards WHSC1 in biochemical and biophysical assays. Furthermore, a crystal structure was solved with the peptide in complex with SAM and the SET domain of WHSC1L1. This inhibitor is an important first step in creating potent, selective WHSC1 tool compounds for the purposes of understanding the complex biology in relation to human disease.</p></div
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
Posttranslational
methylation of histones plays a critical role
in gene regulation. Misregulation of histone methylation can lead
to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2)
methylates histone 3 at lysine 27 (H3K27) and abnormal methylation
of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor
in clinical development, has shown activity in both preclinical models
of cancer as well as in patients with lymphoma or INI1-deficient solid
tumors. Herein we report the structure–activity relationships
from identification of an initial hit in a high-throughput screen
through selection of tazemetostat for clinical development. The importance
of several methyl groups to the potency of the inhibitors is highlighted
as well as the importance of balancing pharmacokinetic properties
with potency
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
<div><p>Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical testing of the EZH2 inhibitor EPZ-6438 has recently begun in patients. We report here that combining EPZ-6438 with CHOP in preclinical cell culture and mouse models results in dramatic synergy for cell killing in <i>EZH2</i> mutant germinal center NHL cells. Surprisingly, we observe that much of this synergy is due to Prednisolone – a glucocorticoid receptor agonist (GRag) component of CHOP. Dramatic synergy was observed when EPZ-6438 is combined with Prednisolone alone, and a similar effect was observed with Dexamethasone, another GRag. Remarkably, the anti-proliferative effect of the EPZ-6438+GRag combination extends beyond EZH2 mutant-bearing cells to more generally impact germinal center NHL. These preclinical data reveal an unanticipated biological intersection between GR-mediated gene regulation and EZH2-mediated chromatin remodeling. The data also suggest the possibility of a significant and practical benefit of combining EZH2 inhibitors and GRag that warrants further investigation in a clinical setting.</p></div
Biochemical and biophysical peptide inhibitor potency values for WHSC1 941–1240 and WHSC1L1 1054–1285<sup>a</sup>.
<p>Biochemical and biophysical peptide inhibitor potency values for WHSC1 941–1240 and WHSC1L1 1054–1285<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0197082#t002fn001" target="_blank"><sup>a</sup></a>.</p
Representative SPR sensorgrams for PTD2 binding to Avi-tagged WHSC1 941–1240 in the absence or presence of SAM analogs.
<p>WHSC1 was immobilized on a streptavidin-coated chip and peptide inhibitor was either injected in the absence of cofactor (left panel), co-injected with SAH (middle panel), or co-injected with SFG (right panel) utilizing a 2-fold, 10-point dilution series ending at a 100 μM top concentration.</p
WHSC1L1 1054–1285 has a similar overall structure in relation to other NSD family proteins and can form a ternary complex with SAM and PTD2.
<p>(A) Superposition of NSD family proteins (green/yellow = WHSC1L1-PTD2 (PDB code = 6CEN); cyan = WHSC1L1 (PDB code = 5UPD); magenta = WHSC1 (PDB code = 5LSU); purple = NSD1 (PDB code = 3OOI). All protein chains are shown as ribbons; SAM and PTD2 are depicted in stick representation. (B) Structure of WHSC1L1-PTD2-SAM ternary complex. Hydrogen bonds are indicated with dashed lines. (C) Superposition of WHSC1L1-PTD2 and SETD2-H3.3 K36M (grey; PDB code = 5JJY).</p
Representative sensorgram for PTD2 binding to Avi-tagged WHSC1 941–1240 from single-cycle kinetic SPR measurements.
<p>WHSC1 was immobilized on a streptavidin-coated chip and peptide inhibitor was co-injected with SAM utilizing a 3-fold, 5-point dilution series ending at a 20 μM top concentration. Data reported in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0197082#pone.0197082.t002" target="_blank">Table 2</a> is presented as the standard deviation of three independent experiments.</p
Norleucine-containing peptides can inhibit WHSC1 and WHSC1L1 activity in vitro.
<p>Representative peptide inhibitor biochemical dose-response curves for (A) WHSC1 941–1240 and (B) WHSC1L1 1054–1285. Error bars represent the standard deviation of three independent replicates. Resulting IC<sub>50</sub> values are reported in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0197082#pone.0197082.t002" target="_blank">Table 2</a>.</p
Isothermal titration calorimetry of PTD2 binding to WHSC1 941–1240.
<p>Upper panel, calorimetric trace for ligand titration; lower panel, binding isotherm from calorimetric trace. WHSC1 concentration in the cell was 10 μM supplemented with 100 μM SAM. PTD2 concentration in the syringe was 100 μM.</p